用于治疗多发性硬化症的埃莫帕米结合蛋白抑制剂
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2023 Sep 6;14(10):1318-1319. doi: 10.1021/acsmedchemlett.3c00366. eCollection 2023 Oct 12.
Abstract
Provided herein are novel emopamil-binding protein (EBP) inhibitors, pharmaceutical compositions, use of such compounds in treating multiple sclerosis, and processes for preparing such compounds.
摘要
本文提供了新型埃莫帕米结合蛋白（EBP）抑制剂、药物组合物、此类化合物在治疗多发性硬化症中的用途以及制备此类化合物的方法。
相似文献
1
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.用于治疗多发性硬化症的埃莫帕米结合蛋白抑制剂
ACS Med Chem Lett. 2023 Sep 6;14(10):1318-1319. doi: 10.1021/acsmedchemlett.3c00366. eCollection 2023 Oct 12.
2
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.用于治疗多发性硬化症的埃莫帕米结合蛋白抑制剂
ACS Med Chem Lett. 2024 Jan 4;15(2):163-164. doi: 10.1021/acsmedchemlett.3c00555. eCollection 2024 Feb 8.
3
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.用于治疗多发性硬化症的埃莫帕米结合蛋白抑制剂
ACS Med Chem Lett. 2023 Oct 30;14(11):1501-1502. doi: 10.1021/acsmedchemlett.3c00457. eCollection 2023 Nov 9.
4
Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.新型异恶唑烷类化合物作为RIPK1抑制剂用于治疗阿尔茨海默病、多发性硬化症和肌萎缩侧索硬化症。
ACS Med Chem Lett. 2024 Apr 2;15(4):447-448. doi: 10.1021/acsmedchemlett.4c00119. eCollection 2024 Apr 11.
5
Discovery and Optimization of Selective Brain-Penetrant EBP Inhibitors that Enhance Oligodendrocyte Formation.发现和优化选择性穿透血脑屏障的 EBP 抑制剂，以增强少突胶质细胞的形成。
J Med Chem. 2024 Mar 28;67(6):4819-4832. doi: 10.1021/acs.jmedchem.3c02396. Epub 2024 Mar 12.
6
Novel Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases.用于治疗神经退行性疾病的新型S1P5调节剂化合物。
ACS Med Chem Lett. 2024 May 5;15(6):750-751. doi: 10.1021/acsmedchemlett.4c00178. eCollection 2024 Jun 13.
7
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的单酰甘油脂肪酶抑制剂的新型杂环化合物。
ACS Med Chem Lett. 2024 Jun 21;15(7):994-995. doi: 10.1021/acsmedchemlett.4c00261. eCollection 2024 Jul 11.
8
Cloning of an emopamil-binding protein (EBP)-like protein that lacks sterol delta8-delta7 isomerase activity.缺乏甾醇δ8-δ7异构酶活性的埃莫帕米结合蛋白（EBP）样蛋白的克隆。
Biochem J. 2003 Aug 15;374(Pt 1):229-37. doi: 10.1042/BJ20030465.
9
Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases.用于治疗多种疾病的新型杂环PAD4抑制剂。
ACS Med Chem Lett. 2024 Jan 23;15(2):179-180. doi: 10.1021/acsmedchemlett.4c00012. eCollection 2024 Feb 8.
10
Carboxylic Acid-Containing Indanyl Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases.含羧酸茚满化合物作为治疗神经退行性疾病的S1P5调节剂
ACS Med Chem Lett. 2023 Jul 12;14(8):1033-1034. doi: 10.1021/acsmedchemlett.3c00272. eCollection 2023 Aug 10.
引用本文的文献
1
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.用于治疗多发性硬化症的埃莫帕米结合蛋白抑制剂
ACS Med Chem Lett. 2024 Jan 4;15(2):163-164. doi: 10.1021/acsmedchemlett.3c00555. eCollection 2024 Feb 8.
2
Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.用于治疗多发性硬化症的埃莫帕米结合蛋白抑制剂
ACS Med Chem Lett. 2023 Oct 30;14(11):1501-1502. doi: 10.1021/acsmedchemlett.3c00457. eCollection 2023 Nov 9.
本文引用的文献
1
Promoting remyelination: A case study in regenerative medicine.促进髓鞘再生：再生医学的案例研究。
Curr Opin Chem Biol. 2022 Oct;70:102201. doi: 10.1016/j.cbpa.2022.102201. Epub 2022 Aug 27.
2
Structural enzymology of cholesterol biosynthesis and storage.胆固醇生物合成和储存的结构酶学。
Curr Opin Struct Biol. 2022 Jun;74:102369. doi: 10.1016/j.sbi.2022.102369. Epub 2022 Apr 7.
3
Impaired metabolism of oligodendrocyte progenitor cells and axons in demyelinated lesion and in the aged CNS.脱髓鞘病变和衰老中枢神经系统中少突胶质前体细胞和轴突代谢受损。
Curr Opin Pharmacol. 2022 Jun;64:102205. doi: 10.1016/j.coph.2022.102205. Epub 2022 Mar 25.
4
Unearthing the Janus-face cholesterogenesis pathways in cancer.揭示癌症中具有两面性的胆固醇生成途径。
Biochem Pharmacol. 2022 Feb;196:114611. doi: 10.1016/j.bcp.2021.114611. Epub 2021 May 16.
Zotero 插件